Marksans Pharma’s UK arm Relonchem has got yet another Medicines and Healthcare products Regulatory Agency’s (MHRA) nod to market one of its anti-allergy medicines.
The UK drug regulator has approved Cetirizine Dihydrochloride 1 mg/ml Oral Solution, used to treat a range of seasonal and year-round allergies.
This approval expands Marksans Pharma's product portfolio in the UK pharmaceutical market.
Earlier this week, Relonchem had got MHRA approval to market Mefenamic Acid film-coated tablets in 250 mg and 500 mg strengths.
This week, Marksan’s US subsidiary received approval from the FDA for an over-the-counter anti-diarrhoeal medicine - Loperamide Hydrochloride Tablets USP.
This back-to-back approvals in the UK and US markets show Marksans increasing global presence.
